Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia
Treatment of patients with acute myeloid leukemia (AML) who do not wish to accept blood product transfusion, including Jehovah's Witnesses, is extremely challenging. The use of conventional chemotherapy for induction of complete remission (CR) results in profound anemia and thrombocytopenia req...
Saved in:
Main Authors: | Ashkan Emadi (Author), Najeebah A. Bade (Author), Brandi Stevenson (Author), Zeba Singh (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2016-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Blood transfusion and Jehovah's Witnesses
by: Monica Vieira da Motta Piacsek, et al.
Published: (2018) -
How does the NPM1 mutant induce leukemia?
by: Paolo Sportoletti
Published: (2011) -
Intercultural Competences in Health Care - Jehovah's Witnesses
by: Elżbieta Bernaciak, et al.
Published: (2019) -
Intercultural Competences in Health Care - Jehovah's Witnesses
by: Elżbieta Bernaciak, et al.
Published: (2019) -
Recent advances of IDH1 mutant inhibitor in cancer therapy
by: Wangqi Tian, et al.
Published: (2022)